Pharmacy

After Leqembi approval, Eisai CEO to retire

Less than a week after Eisai secured a full approval for Leqembi — the first Alzheimer’s drug to achieve full approval — the drugmaker’s CEO announced his plan to retire by the end of July.

By: Paige Twenter

Wednesday, July 12th, 2023

Ivan Cheung, the CEO, president, senior vice president and chair of Eisai, will retire by July 31, according to a July 11 news release. Five executives were promoted, including Tatsuyuki Yasuno, who was CFO and is now acting president of the Americas and CEO and senior vice president of Eisai.

AI in healthcare finance — Why automating the routine is the small prize

Tuesday, September 29

1:00 PM - 2:00 PM CDT

Presenters: Frank Stevens, StrataJosh Wiggins, Strata

Beyond Navigation: How Evry Health and Color Are Transforming Cancer Care for a Fully-Insured Population

Wednesday, September 30

1:00 PM - 2:00 PM CDT

Presenters: Dany Matar, ColorDr. Rebecca Miksad, ColorDr. Glenn Hamilton, Evry HealthChristina Rassi, Evry Health

Next Up in Pharmacy

Millions of Americans could lose access to cheap Canadian prescriptions next month: 3 notes

New customs requirements taking effect Oct. 22 could disrupt access for millions of Americans who buy prescription drugs from Canadian…

By: Ella Jeffries
22 hours ago
AHA seeks permanent 340B rebate ban: 6 things to know

The American Hospital Association is urging Congress to permanently bar rebate models in the 340B program. AHA issued the request…

By: Mackenzie Bean
23 hours ago
FDA approves Eli Lilly's weekly insulin injection

Eli Lilly received FDA approval Sept. 24 for Onswik, a once-weekly basal insulin injection for adults with Type 2 diabetes.…

By: Mackenzie Bean
Yesterday

Comments are closed.

Next Up in Pharmacy

Join the 500,000+ healthcare executives who start their day with Becker's